@article{6c01cce91b634504a0cd8a2e3a82ab6e,
title = "Current directions in tau research: Highlights from Tau 2020",
abstract = "Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.",
keywords = "Alzheimer's, biomarkers, neurodegeneration, tau, therapeutics",
author = "Claire Sexton and Heather Snyder and Dirk Beher and Boxer, {Adam L.} and Pat Brannelly and Brion, {Jean Pierre} and Luc Bu{\'e}e and Cacace, {Angela M.} and Ga{\"e}l Ch{\'e}telat and Martin Citron and DeVos, {Sarah L.} and Kristophe Diaz and Feldman, {Howard H.} and Bess Frost and Goate, {Alison M.} and Michael Gold and Bradley Hyman and Keith Johnson and Karch, {Celeste M.} and Kerwin, {Diana R.} and Koroshetz, {Walter J.} and Irene Litvan and Morris, {Huw R.} and Mummery, {Catherine J.} and James Mutamba and Patterson, {Marc C.} and Quiroz, {Yakeel T.} and Rabinovici, {Gil D.} and Amy Rommel and Shulman, {Melanie B.} and Toledo-Sherman, {Leticia M.} and Stacie Weninger and Wildsmith, {Kristin R.} and Worley, {Susan L.} and Carrillo, {Maria C.}",
note = "Funding Information: This paper is dedicated to the memory of Peter Davies, co-chair of Tau 2020 and chair of the Rainwater Prize Selection Committee. We thank Michel Goedert, Kenneth S. Kosik, and Eliezer Masliah for their contributions to Tau 2020 and the manuscript and acknowledge all the presenters at the conference. Funding Information: Because tau is a complex molecular imaging target, with heterogeneity in biochemistry and in the microstructure of tau aggregates, it is unlikely that a single tau PET tracer will be useful for capturing patterns of spread associated with different non‐AD tauopathies. However, important collaborative efforts are currently under way to optimize the imaging of non‐AD tauopathies, in part by taking advantage of the subtle differences in tau folding revealed by cryo‐EM technology. The Tau Centers Without Walls, funded by a National Institute of Neurological Disorders and Stroke grant, is bringing together tau imaging experts who are dedicated to developing successful new tracers for non‐AD tauopathies. In addition, the Rainwater Charitable Foundation has undertaken a two‐pronged approach to the development of non‐AD tauopathies tracers. First, it created the PIPETTE Consortium (Philanthropic Investments in Pet Tracers) in 2017 as a cofunding partnership with the Michael J. Fox Foundation to leverage efforts toward creation and optimization of specific ɑ‐synuclein and tau ligands. The partners hope to fund promising ligand tracer development at both for‐profit and academic institutions that use best‐practice structure‐based and ligand‐based medicinal chemistry optimization using available high‐resolution cryo‐EM structures of tau and ɑ‐synuclein. Second, through the Tau Consortium, it has convened a multidisciplinary team comprising experts in structural biology, computational chemistry, medicinal chemistry, and biophysics to tackle 4R‐tau specific ligands. These efforts are expected to improve the efficiency of developing optimal ligands in part by using new computation methods that will likely reduce time to development. Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
month = may,
doi = "10.1002/alz.12452",
language = "English (US)",
volume = "18",
pages = "988--1007",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "5",
}